Premium
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib
Author(s) -
Mian Michael,
Pescosta Norbert,
Badiali Stefania,
Cappelletto Paola Cristina,
Marcheselli Luigi,
Luminari Stefano,
Patriarca Francesca,
Zambello Renato,
Pascarella Anna,
Tagariello Giuseppe,
Marabese Alessandra,
Mondello Patrizia,
Billio Atto,
Cortelazzo Sergio
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15645
Subject(s) - bendamustine , thalidomide , lenalidomide , medicine , dexamethasone , multiple myeloma , bortezomib , refractory (planetary science) , phases of clinical research , clinical trial , gastroenterology , oncology , pharmacology , lymphoma , rituximab , physics , astrobiology